Ostivone by Integrative Therapeutics

LIKELY EFFECTIVE

• Osteoporosis. Most clinical research shows that ipriflavone can prevent loss of bone mineral density (BMD) in postmenopausal adults when taken in combination with calcium 1000 mg daily, with or without estrogen. It may also be beneficial in other patients, including oophorectomized adults and those with vitamin D deficiency. Most research in postmenopausal adults with osteoporosis shows that taking ipriflavone orally in combination with calcium 1000 mg daily can prevent loss of BMD or low bone mass (430,432,433,2169,2170,2175,104208), and may actually increase BMD in some patients (428,2173,2175,4756,104208). A meta-analysis of the available clinical research suggests that concomitant calcium must be used in doses of at least 1000 mg daily in order to obtain benefit. A subgroup analysis of four clinical studies utilizing calcium in doses of 500-800 mg daily found no effect on BMD (104208). Taking ipriflavone plus calcium or vitamin D prophylactically also seems to help prevent osteoporosis in postmenopausal adults (2171,2174,104208). Ipriflavone can also significantly reduce osteoporotic pain and seems to be as effective as inhaled calcitonin (432,2175,4756,4757). However, using ipriflavone in combination with low-dose estrogen seems to be more beneficial than ipriflavone alone for preventing osteoporosis. Ipriflavone plus conjugated estrogen 0.3 mg daily and calcium 500-1000 mg daily seems to consistently increase BMD in postmenopausal adults (427,2171,2172). Ipriflavone has also been evaluated in other populations. In oophorectomized adults, taking ipriflavone in combination with conjugated estrogen 0.625 mg daily can decrease loss of BMD better than estrogen or ipriflavone alone (4749). Ipriflavone also seems to prevent loss of BMD induced by the gonadotropin hormone-releasing hormone agonist, leuprolide (Lupron) (10228). Adding calcium provides further benefit (4746).
• Paget disease. There is some evidence that ipriflavone 600 mg or 1200 mg given orally for 30 days can reduce bone pain, serum alkaline phosphatase levels, and hydroxyproline/creatinine excretion in patients with Paget disease (2176). There is insufficient reliable information available about the effectiveness of ipriflavone for its other uses.

(Read more about IPRIFLAVONE)

LIKELY SAFE ...when used orally and appropriately. Ipriflavone seems to be safe when used for up to 3 years (427,428,430,431,432,433,1196,2169,2170,2171,2172) (2173,2174,2175,4749,10228,104208). However, there is concern that ipriflavone can cause subclinical lymphocytopenia in some patients when taken for greater than 6 months (1196,104208).

PREGNANCY AND LACTATION:
Insufficient reliable information available; avoid using.

(Read more about IPRIFLAVONE)

(Read more about IPRIFLAVONE)

General ...Orally, ipriflavone is generally well-tolerated. However, some patients taking ipriflavone can experience epigastric pain, diarrhea, and dizziness (432,104208). There is some concern that ipriflavone can cause lymphocytopenia when used for at least 6 months (1196,104208).

Gastrointestinal ...Orally, ipriflavone can cause epigastric pain and diarrhea in some people (432,104208).

Hematologic ...Orally, ipriflavone was associated with subclinical lymphocytopenia in about 13% of patients in one study. A decrease in lymphocyte counts to less than 500/mcL seems to be most likely to occur after at least 6 months of treatment, although some patients develop lymphocytopenia after a longer duration of use (1196). Lymphocyte counts seem to normalize in most patients within 12 months after discontinuing ipriflavone (1196,104208).

(Read more about IPRIFLAVONE)